KR950014067A - 아릴아미드유도체 - Google Patents

아릴아미드유도체 Download PDF

Info

Publication number
KR950014067A
KR950014067A KR1019930025796A KR930025796A KR950014067A KR 950014067 A KR950014067 A KR 950014067A KR 1019930025796 A KR1019930025796 A KR 1019930025796A KR 930025796 A KR930025796 A KR 930025796A KR 950014067 A KR950014067 A KR 950014067A
Authority
KR
South Korea
Prior art keywords
group
hydroxy
halogen atom
alkoxy
same
Prior art date
Application number
KR1019930025796A
Other languages
English (en)
Other versions
KR100264726B1 (ko
Inventor
테루오 코모토
히로유기 히로타
수수무 사토
마리 오츠카
히데히코 코야
히로유키 미즈노
타다유키 구라이시
Original Assignee
타이도 나오카타
에스에스 세이야쿠 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP32816492A external-priority patent/JP3514784B2/ja
Application filed by 타이도 나오카타, 에스에스 세이야쿠 가부시끼가이샤 filed Critical 타이도 나오카타
Publication of KR950014067A publication Critical patent/KR950014067A/ko
Application granted granted Critical
Publication of KR100264726B1 publication Critical patent/KR100264726B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

다음의 일반식 (1)
[식중, Ar는 기
나프틸기, 피리딜기, 퓨릴기, 티에닐기, 퀴늘릴기 또는 인들릴기를 나타내고, Y는 기
를 나타내고, Q는 -0- 또는 단일결합을 나타내고, Z는 알킬렌기를 나타내고, R4는 히드록시기, 알콕시기 또는 -NH(CH2)mCOOH를 나타낸다]로 표시되는 아릴아미드 유도체를 개시한다.
본 발명의 화합물은 우수한 콜레스테롤 감소작용, 트리글리세라이드 감소작용과 높은 안전성으로 고지혈중 치료 및 예방에 유용하다.

Description

아릴아미드유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 다음의 일반식(1)
    [식중 Ar는 기
    (식중, Rl, R2, 및 R3은 같거나 다르며, 각각은 수소원자, 할로겐원자, 히드록시기, 할로겐원자로 치환되어도 좋은 알킬기, 알콕시기, 알케닐기, 아실아미노기는 카르복실알킬옥시기를 나타낸다). 나프틸기, 피리딜기, 퓨릴기, 티에닐기, 퀴늘릴기 또는 인들릴기를 나타내고, Y는 기
    를 나타내고, Q는 -0- 또는 단일결합을 나
    타내고, Z는 탄소수 1∼3개의 알킬렌기 또는 기(식중, R5, R6는 알칼기를 나타낸다)를 나타내고, R4는 히드록시기, 알콕시기 또는 NH(CH2)mCOOH(식중, m은 1∼3의 정수이다)를 나타낸다]로 표시되는 아릴아미드 유도체.
  2. 제1항에 있어서, 식중 Ar는 기(식중, Rl, R2및 R31항과 같거나 피리딘기이고, Y는 기
    이고 Q는 -0-이고, Z는 기(식중, R5, R6는 제1항과 같다)이며, R4는 히드록시기 또는 알콕 시기인 아릴아미드유도체.
  3. 제1항에 있어서, Ar이 기(식중 R7는 수소원자, 할로겐원자 또는 알킬기를 나타낸다.)이고, Y는 기이며, Q는 -0-이고, Z는 기(식중 R5, R6는 1항 기재 1와 같다)이며, R4는 히드록시기 또는 알콕시기인 아릴아미드 유도체.
  4. 제1항에 있어서, Ar이 할로겐 원자로 치환된 페닐기이고, Y가 기를 이고, Q는 -0- 이며, Z는 기이며, R4는 히드록시기인 아릴아미드 유도체.
  5. 하기 일반식(I)의, 아릴아미드 유도체 또는 생리학적으로 허용되는 염을 함유하는 고지혈증 치료제.
    [식중, Ar는 기
    (식중, Rl, R2, 및 R3은 같거나 다르며, 각각은 수소원자, 할로겐원자, 히드록시기, 할로겐원자로 치환되어도 좋은 알킬기, 알콕시기, 알케닐기, 아실아미노기는 카르복실알킬옥시기를 나타낸다). 나프틸기, 피리딜기, 퓨릴기, 티에닐기, 퀴늘릴기 또는 인들릴기를 나타내고, Y는 기
    를 나타내고, Q는 -0- 또는 단일결합을 나
    타내고, Z는 탄소수 1∼3개의 알킬렌기 또는 기(식중, R5, R6는 알킬기를 나타낸다)를 나타내고, R4는 히드록시기, 알콕시기 또는 -NH(CH2)mCOOH(식중, m은 1∼3의 정수이다)를 나타낸다]
  6. 하기 일반식(1)의 아릴아미드유도체 또는 생리학적으로 허용되는 염을 고지혈증 환자에게 투여함을 특징으로 하는 고지혈증 치료방법.
    [식중, Ar는 기
    (식중, R1, R2, 및 R3'은 같거나 다르며, 각각은 수소원자, 할로겐원자, 히드록시기, 할로겐원자로 치환되어도 좋은 알킬기, 알콕시기, 알케닐기, 아실아미노기는 카르복실알킬옥시기를 나닥낸다). 나프틸기, 피리딜기, 퓨릴기, 티에닐기, 쥐늘릴기 또는 인들릴기를 나타내고, Y는 기
    를 나타내고, Q는 -0- 또는 단일결합을 나타내고, Z는 탄소수 1∼3개의 알킬렌기 또는 기(식중, R5, R6는 알킬기를 나타낸다)를 나타내고, R4는 히드록시기, 알콕시기 또는 -NH(CH2)mCOOH(식중, m은 1∼3의 정수이다)를 나타낸다]
  7. 하기 일반식(I)의 아릴아미드 유도체 또는 생리학적으로 허용되는 염의 약학적 제제로의 용도.
    [식중, Ar는 기
    (식중, Rl, R2, 및 R3은 같거나 다르며, 각각은 수소원자, 할로겐원자, 히드록시기, 할로겐원자로 치환되어도 좋은 알킬기, 알콕시기, 알케닐기, 아실아미노기는 카르복실알킬옥시기를 나타낸다). 나프틸기, 피리딜기, 퓨릴기, 티에닐기, 퀴늘릴기 또는 인들릴기를 나타내고, Y는 기
    를 나타내고, Q는 -0- 또는 단일결합을 나타내고, Z는 탄소수 1∼3개의 알킬렌기 또는 기(식중, R5, R6는 알킬기를 나타낸다)를 나타내고, R4는 히드록시기, 알콕시기 또는 -NH(CH2)mCOOH(식중, m은 1∼3의 정수이다)를 나타낸다]
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930025796A 1992-06-07 1993-11-30 아릴아미드 유도체 KR100264726B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP136119/1993 1992-06-07
JP328164-1992 1992-12-08
JP328164/1992 1992-12-08
JP32816492A JP3514784B2 (ja) 1991-12-11 1992-12-08 アリールアミド誘導体
JP13611993 1993-06-07

Publications (2)

Publication Number Publication Date
KR950014067A true KR950014067A (ko) 1995-06-15
KR100264726B1 KR100264726B1 (ko) 2000-09-01

Family

ID=26469788

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930025796A KR100264726B1 (ko) 1992-06-07 1993-11-30 아릴아미드 유도체

Country Status (9)

Country Link
US (2) US5411972A (ko)
EP (1) EP0607536B1 (ko)
KR (1) KR100264726B1 (ko)
CN (1) CN1035178C (ko)
CA (1) CA2110095A1 (ko)
DE (1) DE69329894T2 (ko)
ES (1) ES2156120T3 (ko)
HK (1) HK1011350A1 (ko)
TW (1) TW237449B (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3842043B2 (ja) * 1998-04-28 2006-11-08 エルビオン アクチエンゲゼルシャフト 新規ヒドロキシインドール、ホスホジエステラーゼ４のインヒビタとしてのその使用及びその製法
US6329044B1 (en) * 1998-06-25 2001-12-11 Asahi Glass Company Ltd. Transparent conductive film and method of making the film
WO2004048334A1 (en) * 2002-11-26 2004-06-10 Pfizer Products Inc. Phenyl substituted piperidine compounds for use as ppar activators
SE0301010D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SA04250253B1 (ar) * 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
EP2380872B1 (en) 2004-06-15 2014-04-23 Cellceutix Corporation Polycationic compounds and uses thereof
GB0415320D0 (en) * 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
MX2007001634A (es) * 2004-08-11 2007-04-23 Kyorin Seiyaku Kk Nuevo derivado de acido amino benzoico ciclico.
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
JP5208510B2 (ja) * 2004-11-23 2013-06-12 アストラゼネカ・アクチエボラーグ 呼吸器疾患の処置に有用なフェノキシ酢酸誘導体
WO2006101108A1 (ja) * 2005-03-23 2006-09-28 Kyorin Pharmaceutical Co., Ltd. 新規環状アミノフェニルアルカン酸誘導体
KR101289995B1 (ko) 2005-09-27 2013-07-26 시오노기 앤드 컴파니, 리미티드 Ｐｇｄ2 수용체 길항제 활성을 갖는 설폰아마이드 유도체
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
US8148572B2 (en) 2005-10-06 2012-04-03 Astrazeneca Ab Compounds
ES2380683T3 (es) * 2005-12-15 2012-05-17 Astrazeneca Ab Difenil-éteres, -amidas, -sulfuros y - metanos sustituidos para el tratamiento de la enfermedad respiratoria
UA100983C2 (ru) * 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
PE20180027A1 (es) 2015-02-06 2018-01-09 Intercept Pharmaceuticals Inc Composiciones farmaceuticas para terapia combinada
BR112021024109A2 (pt) 2019-05-30 2022-03-22 Intercept Pharmaceuticals Inc Composições farmacêuticas compreendendo um agonista fxr e um fibrato para uso no tratamento de doença hepática colestática
WO2024145931A1 (zh) * 2023-01-06 2024-07-11 上海医药工业研究院有限公司 β-catenin/BCL9蛋白蛋白相互作用的小分子抑制剂及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2025518A1 (ko) * 1969-06-05 1970-12-10
DE3139970A1 (de) * 1981-10-08 1983-04-28 Boehringer Mannheim Gmbh, 6800 Mannheim Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
JPS6144817A (ja) * 1984-08-08 1986-03-04 Otsuka Pharmaceut Co Ltd 強心剤
US4959364A (en) * 1985-02-04 1990-09-25 G. D. Searle & Co. Method of treating inflammation, allergy, asthma and proliferative skin disease using heterocyclic amides
JP2610883B2 (ja) * 1987-08-06 1997-05-14 健三 山口 入出力端子の切り換え方法
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
WO1993012086A1 (en) * 1991-12-11 1993-06-24 Ss Pharmaceutical Co., Ltd. Arylamide derivative

Also Published As

Publication number Publication date
TW237449B (ko) 1995-01-01
CA2110095A1 (en) 1994-06-09
EP0607536B1 (en) 2001-01-24
CN1094039A (zh) 1994-10-26
HK1011350A1 (en) 1999-07-09
EP0607536A1 (en) 1994-07-27
US5532371A (en) 1996-07-02
US5411972A (en) 1995-05-02
ES2156120T3 (es) 2001-06-16
DE69329894D1 (de) 2001-03-01
CN1035178C (zh) 1997-06-18
DE69329894T2 (de) 2001-05-03
KR100264726B1 (ko) 2000-09-01

Similar Documents

Publication Publication Date Title
KR950014067A (ko) 아릴아미드유도체
YU69991A (sh) Derivati piridina
KR920021556A (ko) 라파 마이신 이량체
DK0513104T3 (da) Anvendelse af et alfa-tocopherolphosphat eller et af dets derivater til fremstilling af kosmetiske, dermatologiske eller farmaceutiske præparater, og således opnåede præparater
PT1158973E (pt) Utilizacao de derivados de sulfamato para o tratamento dos disturbios do controlo de impulsos
KR920021523A (ko) 신규한 우레아 유도체, 이의 제조 방법 및 이들을 함유하는 약제학적 조성물
RU2000131183A (ru) Производные оксииминоалкановой кислоты
KR900014367A (ko) 피롤리딘 유도체
EA199901015A1 (ru) 4"-замещенные производные 9-деоксо-9а-а3а-9а-гомоэритромицина а
DK1487829T3 (da) Thiadizolylpiperazinderivater, der er nyttige til behandling eller forebyggelse af smerte
NZ337118A (en) 3-piperidyl-4-oxoquinazoline derivatives and pharmaceutical compositions comprising the same useful in treating or preventing arteriosclerotic and/or hyper-lipemia disease, pancreatitis, obesity, hypercholesterolemia and hypertriglyceridemia.
EA200000731A1 (ru) Альфа-аминоамидные производные, полезные в качестве анальгетических агентов
FR2741619B1 (fr) Nouveaux derives de 2,3,5-trimethyl-4-hydroxy-anilides, leur preparation et leur application en therapeutique
KR970059175A (ko) 벤조아진 유도체 또는 그 염 및 이를 함유하는 의약 조성물
BR1100636A (pt) Agente terapêutico para o mal de parkinson, e, derivado da xantina
RU94044454A (ru) Ингибитор аутоимунных заболеваний
KR950703527A (ko) 프로스타글란딘 유도체
KR960022542A (ko) 광학 활성 벤조티에핀 유도체, 그의 제조방법 및 용도
KR900001683A (ko) 피페리딘 유도체
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
KR940702491A (ko) 옥사졸리돈 유도체
KR900018091A (ko) 진경제
KR970701044A (ko) 콜린에스테라제 활성제
DK485489A (da) Amider og nitriler, framaceutiske praeparater indeholdende disse og anvendelse af forbindelserne til fremstilling af laegemidler
KR890012942A (ko) 5-치환된 오르니틴 유도체

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20030522

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee